HUGE : CSE   FSDDF : OTC FSDDF: OTCQB 

HUGE in Cannabinoid Innovation

With experienced healthcare and pharma executives and an advisory board of Leading Researchers, FSD Pharma is advancing research and development to fulfill unmet medical needs.



As seen on:

Advancing R&D to fulfill unmet medical needs.

FSD’s R&D platform focuses on cannabinoids and their potential for widespread clinical applications. With the acquisition of Prismic Pharmaceuticals, they have added an R&D platform with the capability of producing synthetic cannabinoids and opioid sparing compounds that would hopefully gain FDA approval to commercialize prescription medications in United States, Canada & ROW. 

FSD is a science-driven cannabis company that aims to deliver growth and returns to shareholders through the development of innovative pharmaceutical products based on cannabinoids.


PROCESSING & MANUFACTURING

CANNABINOID

EXTRACTION

PHARMA RESEARCH & DEVELOPMENT

The Fundamentals of FSD Pharma are Strong: 

No long term debt

Non-cash assets over $72 M

Raised $4.5M at a premium ($20.10 a share) with a major investment infusion by the CEO, Dr. Raza Bokhari, of $1.5M USD

HUGE NEWS

OPERATIONS

FSD Pharma Launches Online Ordering System for Medicinal Cannabis Fulfillment


LICENSING

FSD Pharma Receives Cannabis Sales License from Health Canada


ACQUISITION

FSD Pharma Closes Deal to Acquire Prismic Pharmaceuticals


Discover More about HUGE

Request Investor Kit!

Powered by:

Copyright © 2019. All rights reserved.